These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 34514186)

  • 21. Influence of treatment with neutralizing monoclonal antibodies on the SARS-CoV-2 nasopharyngeal load and quasispecies.
    Vellas C; Del Bello A; Debard A; Steinmeyer Z; Tribaudeau L; Ranger N; Jeanne N; Martin-Blondel G; Delobel P; Kamar N; Izopet J
    Clin Microbiol Infect; 2022 Jan; 28(1):139.e5-139.e8. PubMed ID: 34537363
    [TBL] [Abstract][Full Text] [Related]  

  • 22. REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19.
    Weinreich DM; Sivapalasingam S; Norton T; Ali S; Gao H; Bhore R; Xiao J; Hooper AT; Hamilton JD; Musser BJ; Rofail D; Hussein M; Im J; Atmodjo DY; Perry C; Pan C; Mahmood A; Hosain R; Davis JD; Turner KC; Baum A; Kyratsous CA; Kim Y; Cook A; Kampman W; Roque-Guerrero L; Acloque G; Aazami H; Cannon K; Simón-Campos JA; Bocchini JA; Kowal B; DiCioccio AT; Soo Y; Geba GP; Stahl N; Lipsich L; Braunstein N; Herman G; Yancopoulos GD;
    N Engl J Med; 2021 Dec; 385(23):e81. PubMed ID: 34587383
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis.
    Siemieniuk RA; Bartoszko JJ; Díaz Martinez JP; Kum E; Qasim A; Zeraatkar D; Izcovich A; Mangala S; Ge L; Han MA; Agoritsas T; Arnold D; Ávila C; Chu DK; Couban R; Cusano E; Darzi AJ; Devji T; Foroutan F; Ghadimi M; Khamis A; Lamontagne F; Loeb M; Miroshnychenko A; Motaghi S; Murthy S; Mustafa RA; Rada G; Rochwerg B; Switzer C; Vandvik PO; Vernooij RW; Wang Y; Yao L; Guyatt GH; Brignardello-Petersen R
    BMJ; 2021 Sep; 374():n2231. PubMed ID: 34556486
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Casirivimab and imdevimab (REGEN-COV) for post-exposure prophylaxis of COVID-19.
    Med Lett Drugs Ther; 2021 Aug; 63(1631):130-131. PubMed ID: 34544100
    [No Abstract]   [Full Text] [Related]  

  • 25. Monoclonal Antibody Therapy for COVID-19 in Solid Organ Transplant Recipients.
    Yetmar ZA; Beam E; O'Horo JC; Ganesh R; Bierle DM; Brumble L; Seville MT; Razonable RR
    Open Forum Infect Dis; 2021 Jun; 8(6):ofab255. PubMed ID: 34631921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B1.617.2 (Delta) surge.
    Bierle DM; Ganesh R; Razonable RR
    J Clin Virol; 2021 Dec; 145():105026. PubMed ID: 34775142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Casirivimab/Imdevimab: First Approval.
    Deeks ED
    Drugs; 2021 Nov; 81(17):2047-2055. PubMed ID: 34716907
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monoclonal antibody treatment for COVID-19 in solid organ transplant recipients.
    Sarrell BA; Bloch K; El Chediak A; Kumm K; Tracy K; Forbes RC; Langone A; Thomas L; Schlendorf K; Trindade AJ; Perri R; Wright P; Concepcion BP
    Transpl Infect Dis; 2022 Feb; 24(1):e13759. PubMed ID: 34787345
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load.
    Dougan M; Azizad M; Mocherla B; Gottlieb RL; Chen P; Hebert C; Perry R; Boscia J; Heller B; Morris J; Crystal C; Igbinadolor A; Huhn G; Cardona J; Shawa I; Kumar P; Blomkalns A; Adams AC; Van Naarden J; Custer KL; Knorr J; Oakley G; Schade AE; Holzer TR; Ebert PJ; Higgs RE; Sabo J; Patel DR; Dabora MC; Williams M; Klekotka P; Shen L; Skovronsky DM; Nirula A
    Clin Infect Dis; 2022 Aug; 75(1):e440-e449. PubMed ID: 34718468
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Consensus statement and recommendations on the treatment of COVID-19: 2021 update.
    Ko HK; Yu WK; Pan SW; Chen WC; Yang KY; Lin YT; Wang FD; Yang MH; Chen YM;
    J Chin Med Assoc; 2022 Jan; 85(1):5-17. PubMed ID: 34524227
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study.
    Moor MB; Suter-Riniker F; Horn MP; Aeberli D; Amsler J; Möller B; Njue LM; Medri C; Angelillo-Scherrer A; Borradori L; Radonjic-Hoesli S; Seyed Jafari SM; Chan A; Hoepner R; Bacher VU; Mani LY; Iype JM; Hirzel C; Maurer B; Sidler D
    Lancet Rheumatol; 2021 Nov; 3(11):e789-e797. PubMed ID: 34514436
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated Individuals with High-Risk Comorbidities.
    Bierle DM; Ganesh R; Tulledge-Scheitel S; Hanson SN; Arndt LL; Wilker CG; Razonable RR
    J Infect Dis; 2022 Feb; 225(4):598-602. PubMed ID: 34791298
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of chronic or relapsing COVID-19 in immunodeficiency.
    Brown LK; Moran E; Goodman A; Baxendale H; Bermingham W; Buckland M; AbdulKhaliq I; Jarvis H; Hunter M; Karanam S; Patel A; Jenkins M; Robbins A; Khan S; Simpson T; Jolles S; Underwood J; Savic S; Richter A; Shields A; Brown M; Lowe DM
    J Allergy Clin Immunol; 2022 Feb; 149(2):557-561.e1. PubMed ID: 34780850
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vaccinated patients have reduced rates of hospitalization after receiving casirivimab and imdevimab for COVID-19.
    Zitek T; Jodoin K; Kheradia T; Napolillo R; Dalley MT; Quenzer F; Farcy DA
    Am J Emerg Med; 2022 Jun; 56():370-371. PubMed ID: 34763963
    [No Abstract]   [Full Text] [Related]  

  • 35. Regdanvimab: First Approval.
    Syed YY
    Drugs; 2021 Dec; 81(18):2133-2137. PubMed ID: 34724174
    [TBL] [Abstract][Full Text] [Related]  

  • 36. COVID-19: A Review of Potential Treatments (Corticosteroids, Remdesivir, Tocilizumab, Bamlanivimab/Etesevimab, and Casirivimab/Imdevimab) and Pharmacological Considerations.
    Nhean S; Varela ME; Nguyen YN; Juarez A; Huynh T; Udeh D; Tseng AL
    J Pharm Pract; 2023 Apr; 36(2):407-417. PubMed ID: 34597525
    [No Abstract]   [Full Text] [Related]  

  • 37. Real-world experience with anti-PD-1/PD-L1 monotherapy in patients with non-small cell lung cancer : A retrospective Austrian multicenter study.
    Geiger-Gritsch S; Olschewski H; Kocher F; Wurm R; Absenger G; Flicker M; Hermann A; Heininger P; Fiegl M; Zechmeister M; Endel F; Wild C; Pall G
    Wien Klin Wochenschr; 2021 Nov; 133(21-22):1122-1130. PubMed ID: 34528126
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab.
    Cattaneo C; Cancelli V; Imberti L; Dobbs K; Sottini A; Pagani C; Belotti A; Re A; Anastasia A; Quaresima V; Tucci A; Chiorini JA; Su HC; Cohen JI; Burbelo PD; Rossi G; Notarangelo LD
    Blood Cancer J; 2021 Sep; 11(9):151. PubMed ID: 34521813
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lack of effect on in-hospital mortality of drugs used during COVID-19 pandemic: Findings of the retrospective multicenter COVOCA study.
    Pafundi PC; Galiero R; Simeon V; Rinaldi L; Perrella A; Vetrano E; Caturano A; Alfano M; Beccia D; Nevola R; Marfella R; Sardu C; Coppola C; Scarano F; Maggi P; De Lucia Sposito P; Vocciante L; Rescigno C; Sbreglia C; Fraganza F; Parrella R; Romano A; Calabria G; Polverino B; Pagano A; Bologna C; Amitrano M; Esposito V; Coppola N; Maturo N; Adinolfi LE; Chiodini P; Sasso FC;
    PLoS One; 2021; 16(9):e0256903. PubMed ID: 34520465
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.